查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858267

擴大性心肌病治療市場依治療分類、治療方法、給藥途徑、最終用戶和分銷管道分類－2025-2032年全球預測

Dilated Cardiomyopathy Therapeutics Market by Therapeutic Class, Treatment Modality, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，擴大性心肌病治療市場將成長至 8.3962 億美元，複合年成長率為 7.90%。

主要市場統計數據
基準年 2024 4.5676億美元
預計年份：2025年 4.9366億美元
預測年份：2032年 8.3962億美元
複合年成長率 (%) 7.90%

本書權威地介紹了擴張型心肌病變治療的臨床複雜性、跨學科護理的演變以及塑造現代擴大性心肌病治療的創新動態。

擴大性心肌病（DCM）是一種複雜的臨床症候群，其特徵是心室擴張和收縮功能障礙，導致不同患者群體中出現顯著的發病率和死亡率。過去十年，治療策略已從傳統的神經激素阻斷擴展到包括先進的器械介入和針對遺傳及分子因素的精準醫療。這種發展迫使相關人員重新評估診療路徑、資源分配和長期管理模式，以反映漸進式改善和突破性創新。

醫療器材創新、精準生技藥品和醫療保健服務重新設計的獎勵，從根本上重塑了擴大性心肌病的治療管道和相關人員。

擴大性心肌病的治療格局正在經歷一場變革，這主要得益於技術進步、監管法規的演變以及醫療服務模式的改變。曾經挽救生命的醫療設備，隨著越來越多的證據表明其對降低發病率和提高生存率的影響，正被更早地整合到臨床診療流程中；與此同時，醫療器械的小型化和遠程監測能力也在重塑門診管理和隨訪的模式。

評估2025年關稅變化對全球用於治療心肌病的醫療器材、生技藥品和基因治療材料的製造、採購和定價策略的影響

2025年生效的新關稅將顯著增加擴大性心肌病治療的全球供應鏈和成本結構的複雜性，尤其是那些國際分銷的組件和生技藥品。心臟再同步治療系統、植入式心臟整流去顫器和心室輔助裝置等醫療設備都依賴複雜的全球製造網路，包括半導體、感測器和特種合金。上游供應商面臨的關稅成本壓力可能會波及到器械製造商，從而給醫院和採購商帶來價格壓力。

將治療領域、治療治療方法、給藥途徑、臨床環境和分銷管道與臨床和商業策略聯繫起來的綜合細分分析

從細分角度分析擴大性心肌病治療，透過考慮治療分類、治療治療方法、給藥途徑、終端用戶環境和分銷管道，可以揭示不同的治療機會和應用趨勢。將治療層級分為ACE抑制劑、ARB、ARNI、 BETA阻斷劑、器械療法、利尿劑和基因療法，可以發現，儘管藥物療法仍然是基礎，但器械療法和基因療法具有獨特的臨床和商業性特性。將器械療法進一步細分為CRT、ICD和VAD，可凸顯不同的投資需求和治療路徑需求。依治療方法類型（器械療法、基因療法和藥物療法）進行分析，並認知到藥物研發分為生技藥品和小分子藥物，可以突出研發風險和監管複雜性交彙的領域，以及更適合進行漸進式臨床最佳化的領域。

區域趨勢分析：美洲、歐洲、中東、非洲和亞太地區監管、報銷和基礎設施的差異對治療方法採納和取得的影響

區域趨勢正在以不同的方式影響擴大性心肌病治療的研發、應用和交付，美洲、歐洲、中東和非洲以及亞太地區的情況。在美洲，成熟的醫療基礎設施和完善的報銷體系支持先進醫療設備和新一代生物製藥的快速應用，但支付方越來越要求提供嚴格的衛生經濟學證據來證明高成本治療性介入的合理性。臨床網路和專科卓越中心推動了複雜手術和實驗室檢測的參與，而私人和公共支付方正在就醫療保險條款進行談判，這將影響商業化策略。

企業策略與競爭策略：醫療設備領導者、生技藥品開發商和基因治療先驅如何整合自身能力以獲得長期優勢

擴大性心肌病治療領域的格局呈現出大規模多元化醫療設備製造商、專業生技藥品開發商和新興基因治療創新者之間策略融合的趨勢。成熟的循環系統醫療設備公司持續投資於下一代植入式系統、遠端監測環境和手術全期服務模式，以改善患者的長期預後並創造持續的業務收益。這些現有企業正積極尋求補充性收購、合作開發夥伴關係和廣泛的臨床項目，以保持其在器械領域的領先地位，並拓展至增值相關服務領域。

領導者在推動跨治療方法和臨床環境的證據產生、供應鏈韌性和整合商業化方面所面臨的實際策略挑戰

為了在擴大性心肌病治療領域創造臨床和商業性價值，產業領導者應採取多管齊下的策略，優先考慮實證醫學證據的累積、供應鏈的韌性以及整合式商業化。首先，透過務實的測試、真實世界證據計畫和註冊登記來加強證據基礎至關重要，這有助於說服臨床醫生和支付方認可其帶來的增量效益，尤其對於高成本的醫療設備和基因療法而言。建構一個能夠進行長期療效追蹤的互通性資料平台，將有助於進行價值評估並履行上市後承諾。

這份高階主管分析報告採用透明的調查方法，結合文獻回顧、相關人員訪談、臨床註冊分析和情境評估，得出可靠的策略結論。

本執行分析所依據的研究結合了對同儕審查文獻、監管申報文件和臨床試驗註冊庫的系統性回顧，以及針對整個生態系統的重點基礎研究。文獻綜述納入了最新的指南共識聲明和具有影響力的臨床研究，以確保與目前的醫療標準保持一致。透過審查臨床試驗註冊庫和公開的監管申報文件，我們整理了醫療設備和基因治療候選藥物的臨床實驗項目和預期里程碑。

權威的綜合分析重點闡述了臨床創新、證據深度和操作適應性在擴大性心肌病治療中如何決定未來治療方案的採納和可及性。

擴大性心肌病治療正處於轉折點，醫療設備創新、生技藥品和基因組醫學的融合拓展了治療的可能性，同時也增加了研發、交付和報銷管道的複雜性。能夠將臨床嚴謹性與營運靈活性相結合的相關人員，將更有能力將科學進步轉化為有意義的患者療效和永續的商業模式。不斷變化的醫療保健格局要求重新調整投資重點，並專注於循證醫學、區域供應鏈策略和價值驅動的商業化。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 針對擴大性心肌病肌節蛋白突變的基因治療取得進展
  • 穿戴式心臟監測設備在擴大性心肌病病變患者早期檢測心室功能障礙的臨床應用
  • 引入新型肌凝蛋白調節劑以改善擴大性心肌病治療的左心室射血分數
  • 開發RNA干擾療法以抑制擴大性心肌病中通道的適應不良性重塑
  • 擴大多學科心臟衰竭診療範圍，納入遺傳諮詢和個人化醫療方法
  • 利用心臟磁振造影應變變成像生物標記指導擴大性心肌病患者的治療決策
  • 腸道菌叢調節在抑制擴大性心肌病發炎進展的新興作用
  • 監管加速推進用於擴大性心肌病心肌再生的新型細胞療法

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療類別擴大性心肌病治療市場

  • ACE抑制劑
  • ARB
  • ARNI
  • BETA阻斷劑
  • 器械療法
    • CRT
    • ICD
    • 輔助人工心臟（VAD）
  • 利尿劑
  • 基因治療

第9章擴大性心肌病治療市場（依治療方法）

  • 基於設備的
  • 基因治療
  • 藥物治療
    • 生技藥品
    • 低分子化合物

第10章 依給藥途徑擴大性心肌病治療市場

  • 靜脈注射
  • 口服

第11章擴大性心肌病治療市場（依最終用戶分類）

  • 居家醫療
  • 醫院
  • 專科診所

第12章擴大性心肌病治療市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章擴大性心肌病治療市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章擴大性心肌病治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國擴大性心肌病治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Boehringer Ingelheim International GmbH
    • Novartis International AG
    • AstraZeneca PLC
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Medtronic plc
    • Boston Scientific Corporation
    • Abbott Laboratories
    • Amgen Inc.
    • Laboratoires Servier SAS
Product Code: MRR-8E22B61932B4

The Dilated Cardiomyopathy Therapeutics Market is projected to grow by USD 839.62 million at a CAGR of 7.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 456.76 million
Estimated Year [2025] USD 493.66 million
Forecast Year [2032] USD 839.62 million
CAGR (%) 7.90%

An authoritative introduction framing the clinical complexity, multidisciplinary care evolution, and innovation dynamics shaping modern dilated cardiomyopathy therapeutics

Dilated cardiomyopathy (DCM) represents a complex clinical syndrome characterized by ventricular dilation and systolic dysfunction that leads to substantial morbidity and mortality across diverse patient populations. Over the past decade, therapeutic strategies have expanded beyond traditional neurohormonal blockade to include advanced device interventions and precision medicines that target genetic and molecular drivers. This evolution compels stakeholders to reassess care pathways, resource allocation, and long-term management models to reflect both incremental improvements and step-change innovations.

Clinical practice is adapting to a more heterogeneous patient profile, where early identification of genetic etiologies and nuanced phenotyping inform personalized treatment plans. As a result, multidisciplinary teams spanning cardiology, electrophysiology, genetics, and allied health professionals are increasingly central to therapy selection and ongoing monitoring. Payers and health systems are likewise recalibrating coverage frameworks to address up-front costs associated with devices and gene-based interventions while evaluating downstream reductions in hospitalizations and complications.

From an innovation perspective, the interplay between device engineering, biologic therapeutics, and small-molecule optimization has created a richer set of options for clinicians and patients. Consequently, strategic planning in this therapeutic area requires a granular understanding of segment dynamics, regulatory trajectories, clinical trial readouts, and real-world evidence as they converge to influence adoption, care delivery, and investment priorities.

How converging device innovation, precision biologics, and care delivery redesign are fundamentally reshaping therapeutic pathways and stakeholder incentives in dilated cardiomyopathy

The therapeutic landscape for dilated cardiomyopathy is undergoing transformative shifts driven by converging technological advances, regulatory evolution, and changing care delivery models. Devices that once served as rescue interventions are now being integrated earlier in clinical pathways as evidence accumulates about their impact on morbidity and survival, while miniaturization and remote-monitoring capabilities are reshaping outpatient management and follow-up intensity.

Simultaneously, precision medicine is moving from promise to practice. Gene therapies and targeted biologics are advancing through clinical development with increasingly sophisticated patient selection strategies that leverage genetic testing and biomarker profiling. This is accompanied by a rethinking of clinical trial designs toward adaptive models and real-world endpoints that better reflect heterogeneous patient populations. The pharmacological landscape remains important, with refined small molecules and novel biologic constructs aimed at neurohormonal modulation and myocardial remodeling complementing device-based modalities.

Distribution and care settings are being reimagined; hospitals remain centers of acute care and implantation, but a shift toward homecare, remote titration, and specialty clinics for longitudinal management is evident. These delivery changes are enabled by digital health platforms, interoperability between monitoring devices and electronic records, and greater emphasis on patient-reported outcomes. Collectively, these shifts are not incremental but structural, altering how products are developed, positioned, and reimbursed, and placing a premium on integrated strategies that bridge devices, biologics, and services.

Assessment of how 2025 tariff shifts are reshaping global manufacturing, procurement, and pricing strategies across devices, biologics, and gene therapy inputs in cardiomyopathy care

The introduction of new tariff measures in 2025 adds a significant layer of complexity to global supply chains and cost structures in dilated cardiomyopathy therapeutics, particularly for components and biologic inputs that cross international borders. Medical devices such as cardiac resynchronization therapy systems, implantable cardioverter-defibrillators, and ventricular assist devices depend on intricate global manufacturing networks for semiconductors, sensors, and specialized alloys. Tariff-induced cost pressures on upstream suppliers can cascade to device manufacturers, creating potential pricing tensions for hospitals and purchasers.

On the pharmacological and gene therapy side, manufacturing inputs for vectors, viral production, and complex biologic reagents often involve cross-border sourcing of raw materials and specialized processing equipment. Increased import duties or customs friction can lengthen lead times and raise production costs, prompting sponsors to re-evaluate contract manufacturing strategies, regionalize production, or accelerate technology transfers. These operational responses can mitigate exposure but require capital investment and regulatory coordination that take time to realize.

For health systems and payers, the net effect of tariff-driven cost changes may be felt through procurement cycles and capital budgeting for device programs, as well as through negotiated pricing for high-cost biologics and gene-based therapeutics. In response, manufacturers may pursue differentiated pricing models, local manufacturing partnerships, or outcomes-based contracting to preserve access while maintaining commercial viability. Finally, regulatory and reimbursement stakeholders are likely to scrutinize value propositions more closely, linking coverage decisions to robust clinical and economic evidence as part of a broader adaptation to changing input costs.

Integrated segmentation insights that connect therapeutic classes, treatment modalities, administration routes, care settings, and distribution channels to clinical and commercial strategy

A segmentation-aware view of dilated cardiomyopathy therapeutics reveals differentiated opportunities and adoption dynamics when consideration is given to therapeutic class, treatment modality, administration route, end-user environment, and distribution pathway. When therapeutic class is parsed into ACE inhibitor, Arb, Arni, Beta Blocker, Device Therapy, Diuretic, and Gene Therapy, it becomes clear that medical management remains foundational while device therapy and gene therapy introduce distinct clinical and commercial characteristics; further granularity in device therapy across Crt, Icds, and Vad highlights heterogeneous investment and care pathway requirements. Looking through the lens of treatment modality-Device Based, Gene Therapy, and Pharmacological-and recognizing that pharmacological development bifurcates into Biologics and Small Molecule approaches-clarifies where development risk and regulatory complexity converge versus where incremental clinical optimization is more feasible.

Route of administration further stratifies operational considerations: Intravenous modalities carry implications for inpatient or clinic-based delivery infrastructures, whereas Oral therapies enable broader outpatient management and adherence-focused interventions. End user segmentation across Homecare, Hospital, and Specialty Clinic settings emphasizes shifting touchpoints for follow-up, titration, and device monitoring, with homecare growth accelerating needs for remote monitoring and caregiver support. Finally, distribution channel differentiation among Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies shapes logistics, inventory strategies, and patient access patterns, influencing how manufacturers and payers design distribution agreements and patient support programs.

Integrating these segmentation dimensions enables a clearer mapping of clinical value to commercial levers. For example, gene therapy candidates may require specialized distribution and hospital-based administration while oral small molecules can be deployed broadly through retail pharmacies. Devices necessitate capital procurement and post-implant surveillance, elevating the importance of durable service agreements and interoperability with clinical IT systems. Understanding these intersections is critical for prioritizing R&D investments, tailoring market access plans, and designing patient-centered support models.

Regional dynamics analysis describing how heterogeneous regulatory, reimbursement, and infrastructure factors in the Americas, EMEA, and Asia-Pacific influence therapy adoption and access

Regional dynamics are shaping the development, adoption, and delivery of dilated cardiomyopathy therapeutics in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, mature care infrastructures and well-established reimbursement frameworks support rapid adoption of advanced devices and next-generation biologics, though payers increasingly demand rigorous health-economic evidence to justify high-cost interventions. Clinical networks and specialized centers of excellence facilitate complex procedures and clinical trial enrollment, while private and public payers negotiate coverage conditions that influence commercialization strategies.

Across Europe, Middle East & Africa, the region exhibits considerable heterogeneity driven by national regulatory, reimbursement, and health system structures. Western European markets often mirror North American pathways with structured adoption of devices and biologics, whereas emerging markets within the region face capacity constraints that may delay deployment of complex therapies. Policy emphasis on cost-effectiveness and centralized HTA processes shapes pricing strategies and can incentivize local evidence generation or managed entry agreements.

In the Asia-Pacific region, rapid investments in hospital infrastructure and a growing emphasis on cardiovascular disease management are expanding patient access to advanced therapies. Regulatory pathways in several jurisdictions have been modernized to facilitate expedited review for innovative therapeutics, and local manufacturing initiatives are increasingly pursued to reduce import dependency. Regional collaboration and harmonization efforts are creating new avenues for clinical research and could accelerate broader adoption of device-based and gene-focused interventions when combined with strategic partnerships and localized market access approaches.

Corporate positioning and competitive maneuvers revealing how device leaders, biologics developers, and gene therapy pioneers are aligning capabilities for long-term advantage

The corporate landscape in dilated cardiomyopathy therapeutics is marked by strategic convergence between large diversified device manufacturers, specialist biologics developers, and emerging gene therapy innovators. Established cardiovascular device firms continue to invest in next-generation implantable systems, remote monitoring ecosystems, and peri-procedural service models that enhance long-term patient outcomes and create recurring service revenues. These incumbents often pursue bolt-on acquisitions, co-development partnerships, and broad-based clinical programs to sustain device leadership while expanding into adjacent value-added services.

Biopharmaceutical companies with cardiovascular portfolios are diversifying through targeted biologics and small-molecule programs that address myocardial remodeling and neurohormonal pathways. Simultaneously, biotechnology firms focused on gene editing and vectorized gene replacement are advancing candidates that target defined genetic etiologies of dilated cardiomyopathy, fostering collaborations with manufacturing specialists and clinical research networks to manage development complexity and scale-up risks. Cross-sector alliances between device makers and biologic developers are becoming more common, particularly where combination therapies or diagnostic-enabled patient selection can enhance therapeutic impact.

Competitive differentiation increasingly hinges on evidentiary depth, post-market surveillance capabilities, and the ability to demonstrate real-world value. Companies that invest in longitudinal data platforms, patient support programs, and integrated care solutions are better positioned to engage payers and care providers. Moreover, strategic moves such as regional manufacturing investments, outcomes-based contracting pilots, and early engagement with regulatory agencies are shaping which players can effectively translate scientific advances into sustainable commercial success.

Actionable strategic imperatives for leaders to fortify evidence generation, supply resilience, and integrated commercialization across therapeutics and care settings

Industry leaders should pursue a multi-dimensional strategy that prioritizes evidence generation, supply chain resilience, and integrated commercialization to capture clinical and commercial value in dilated cardiomyopathy therapeutics. First, strengthening the evidence base through pragmatic trials, real-world evidence programs, and registries will be essential to convince clinicians and payers of incremental benefits, particularly for high-cost devices and gene-based therapies. Building interoperable data platforms that facilitate long-term outcome tracking will support value-based conversations and post-market commitments.

Second, diversifying manufacturing footprints and establishing qualified regional partners can mitigate tariff and logistics risks while reducing lead times for critical inputs. Investing in technology transfer and quality systems in strategically selected regions will enable faster response to demand shifts and regulatory requirements. Third, commercial strategies must be aligned to care settings: tailored access programs for hospital procurement, streamlined pathways for specialty clinics, and patient adherence solutions for oral therapies will improve uptake across end-user segments.

Finally, forging cross-sector partnerships-linking device capabilities with pharmacological innovations and digital health tools-can create differentiated offerings that address both clinical and operational pain points. Leaders should also engage early with regulators and HTA bodies to co-design evidence packages and explore innovative reimbursement arrangements. Executed together, these actions will help organizations navigate evolving policy environments, demonstrate sustainable value, and enhance patient access to advanced therapies.

Transparent methodology integrating literature synthesis, stakeholder interviews, clinical registry analysis, and scenario evaluations to support robust strategic conclusions

The research underpinning this executive analysis combined a structured review of peer-reviewed literature, regulatory filings, and clinical trial registries with targeted primary engagements across the ecosystem. Literature synthesis included recent guidelines, consensus statements, and high-impact clinical studies to ensure alignment with current standards of care. Clinical trial registries and public regulatory filings were examined to map investigational programs and expected milestones for device and gene therapy candidates.

Primary research consisted of interviews with cardiologists, electrophysiologists, health system procurement leads, clinical researchers, and patient advocacy representatives to capture front-line perspectives on adoption barriers and clinical unmet needs. These qualitative insights were triangulated with secondary sources, including manufacturing and supply chain publications, technology briefs, and policy analyses, to assemble a holistic view of operational and regulatory dynamics. Data quality protocols involved cross-validation of key assertions against multiple independent sources and sensitivity checks to identify areas of higher uncertainty.

Analytical approaches included segmentation mapping across therapeutic class, modality, administration route, end user, and distribution channel, as well as scenario-based assessment of tariff and supply chain impacts. The methodology emphasized transparency in assumptions and explicit documentation of evidence sources to facilitate verification and to support subsequent deep-dive investigations.

A conclusive synthesis highlighting how clinical innovation, evidence depth, and operational adaptability will determine future adoption and access in dilated cardiomyopathy care

Dilated cardiomyopathy therapeutics are at an inflection point where device innovation, biologic advancement, and genomic medicine are converging to expand treatment possibilities while simultaneously increasing complexity across development, delivery, and reimbursement pathways. Stakeholders who can integrate clinical rigor with operational agility will be best positioned to translate scientific progress into meaningful patient outcomes and sustainable commercial models. The evolving care landscape requires a recalibration of investment priorities, with emphasis on evidence generation, regional supply chain strategies, and value-aligned commercialization.

Adoption trajectories will be shaped not only by clinical efficacy but also by the ability to demonstrate real-world benefit, manage total cost of care, and adapt to shifting policy environments such as tariff-induced supply changes and evolving HTA expectations. Cross-disciplinary collaboration among clinicians, manufacturers, payers, and regulators will be essential to navigate these dynamics and to create durable pathways for patient access. Ultimately, the organizations that combine scientific excellence with pragmatic delivery models and strong stakeholder engagement will set the cadence for the next era of dilated cardiomyopathy care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in gene therapy targeting sarcomeric protein mutations in dilated cardiomyopathy
  • 5.2. Clinical integration of wearable cardiac monitoring devices for early detection of ventricular dysfunction in DCM patients
  • 5.3. Adoption of novel myosin modulators to improve left ventricular ejection fraction in DCM management
  • 5.4. Development of RNA interference therapies to silence maladaptive remodeling pathways in dilated cardiomyopathy
  • 5.5. Expansion of multidisciplinary heart failure clinics incorporating genetic counseling and personalized medicine approaches
  • 5.6. Use of cardiac MRI strain imaging biomarkers to guide therapeutic decisions for dilated cardiomyopathy patients
  • 5.7. Emerging role of gut microbiome modulation in attenuating inflammatory progression in dilated cardiomyopathy
  • 5.8. Regulatory acceleration of novel cell-based therapies for myocardial regeneration in dilated cardiomyopathy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dilated Cardiomyopathy Therapeutics Market, by Therapeutic Class

  • 8.1. Ace Inhibitor
  • 8.2. Arb
  • 8.3. Arni
  • 8.4. Beta Blocker
  • 8.5. Device Therapy
    • 8.5.1. Crt
    • 8.5.2. Icds
    • 8.5.3. Vad
  • 8.6. Diuretic
  • 8.7. Gene Therapy

9. Dilated Cardiomyopathy Therapeutics Market, by Treatment Modality

  • 9.1. Device Based
  • 9.2. Gene Therapy
  • 9.3. Pharmacological
    • 9.3.1. Biologics
    • 9.3.2. Small Molecule

10. Dilated Cardiomyopathy Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Dilated Cardiomyopathy Therapeutics Market, by End User

  • 11.1. Homecare
  • 11.2. Hospital
  • 11.3. Specialty Clinic

12. Dilated Cardiomyopathy Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Dilated Cardiomyopathy Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dilated Cardiomyopathy Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dilated Cardiomyopathy Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Boehringer Ingelheim International GmbH
    • 16.3.2. Novartis International AG
    • 16.3.3. AstraZeneca PLC
    • 16.3.4. Johnson & Johnson
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. Medtronic plc
    • 16.3.7. Boston Scientific Corporation
    • 16.3.8. Abbott Laboratories
    • 16.3.9. Amgen Inc.
    • 16.3.10. Laboratoires Servier SAS

LIST OF FIGURES

  • FIGURE 1. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-